Homozygous Familial Hypercholesterolemia (HoFH) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032
Homozygous familial hypercholesterolemia (HoFH) is a genetic disorder that causes severe elevations in low-density lipoproteins cholesterol (LDL-C) and total cholesterol. Those with HoFH have a very high chance of premature coronary artery disease. Familial hypercholesterolemia is a deficiency or absence of the LDL-C receptors. It can also be caused by mutations of the apolipoprotein B-100 (apoB-100) binding site on LDL-C receptors, PCSK9, and LDLRAP1. The LDLR gene is located on the short arm of chromosome 19.6 LDL-C receptors are responsible for about 70% of the uptake of circulating LDL-C molecules into the liver. Reductions in the number of LDL-C receptors lead to an accelerated deposition of cholesterol on the walls of arteries. The arteries then harden and narrow and reduce the flow of blood. This reduction in blood flow can lead to cardiovascular diseases like stroke and myocardial infarction.
· In 2020, the estimated prevalence of HoFH in the United States was around 1 to 2.5 cases per 160,000 to 300,000 persons, a significant increase from previous estimates.
Thelansis’s “Homozygous Familial Hypercholesterolemia (HoFH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Homozygous Familial Hypercholesterolemia (HoFH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Homozygous Familial Hypercholesterolemia (HoFH) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Homozygous Familial Hypercholesterolemia (HoFH) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
